Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status
Y Adachi, A Tamiya, Y Taniguchi, T Enomoto… - Cancer …, 2020 - Wiley Online Library
Background Nivolumab has promising efficacy for the treatment of non‐small cell lung
cancer (NSCLC). Various predictive factors for nivolumab response in those with NSCLC …
cancer (NSCLC). Various predictive factors for nivolumab response in those with NSCLC …
Efficacy of nivolumab and pembrolizumab in patients with advanced non–small-cell lung cancer needing treatment interruption because of adverse events: a …
D Ksienski, ES Wai, N Croteau, L Fiorino, E Brooks… - Clinical lung cancer, 2019 - Elsevier
Introduction The programmed death 1 antibodies (PD-1 Ab) nivolumab and pembrolizumab
improve overall survival (OS) in advanced non–small-cell lung cancer (NSCLC). We …
improve overall survival (OS) in advanced non–small-cell lung cancer (NSCLC). We …
[HTML][HTML] Italian nivolumab expanded access program in nonsquamous non–small cell lung cancer patients: results in never-smokers and EGFR-mutant patients
MC Garassino, AJ Gelibter, F Grossi, R Chiari… - Journal of Thoracic …, 2018 - Elsevier
Introduction Nivolumab is the first checkpoint inhibitor approved for the treatment of
nonsquamous NSCLC. We report results from the nivolumab Italian expanded access …
nonsquamous NSCLC. We report results from the nivolumab Italian expanded access …
[HTML][HTML] The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in the treatment of advanced non-small cell lung cancer
R Chen, Y Tao, L Shan, H Jiang, F Cai… - Discovery …, 2018 - discoverymedicine.com
Currently, platinum-based chemotherapy is the standard first-line treatment for advanced
non-small cell lung cancer (NSCLC) that is not driven by identifiable genetic events, such as …
non-small cell lung cancer (NSCLC) that is not driven by identifiable genetic events, such as …